[
  {
    "ts": null,
    "headline": "Top Analyst Reports for Broadcom, Merck & Qualcomm",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co. (MRK) and Qualcomm (QCOM), as well as a micro-cap stock, Natural Health Trends Corp. (NHTC).",
    "url": "https://finnhub.io/api/news?id=de69c5a2274445eb3b763f09cc9cc8a4dbf6d039f2afac4c810dc01310b16760",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732225740,
      "headline": "Top Analyst Reports for Broadcom, Merck & Qualcomm",
      "id": 131550855,
      "image": "https://media.zenfs.com/en/zacks.com/76b77267780db8a8e104d16effc1eb76",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co. (MRK) and Qualcomm (QCOM), as well as a micro-cap stock, Natural Health Trends Corp. (NHTC).",
      "url": "https://finnhub.io/api/news?id=de69c5a2274445eb3b763f09cc9cc8a4dbf6d039f2afac4c810dc01310b16760"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=24301fac8d803278d0397803c629b93746b794f80911c405ff1b137c28f4d874",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732206900,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 131599256,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=24301fac8d803278d0397803c629b93746b794f80911c405ff1b137c28f4d874"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Corefolio Allocation Fund Q3 2024 Commentary",
    "summary": "Franklin Corefolio Allocation Fund seeks capital appreciation through a diversified, multidisciplined approach. Read more here.",
    "url": "https://finnhub.io/api/news?id=fcc06068c3ec693b4884222ce6899038c753f92f8972f5db9e4b7b24d6ca0a52",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732189680,
      "headline": "Franklin Corefolio Allocation Fund Q3 2024 Commentary",
      "id": 131541199,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453953453/image_1453953453.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Franklin Corefolio Allocation Fund seeks capital appreciation through a diversified, multidisciplined approach. Read more here.",
      "url": "https://finnhub.io/api/news?id=fcc06068c3ec693b4884222ce6899038c753f92f8972f5db9e4b7b24d6ca0a52"
    }
  },
  {
    "ts": null,
    "headline": "Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities",
    "summary": "RAHWAY, N.J., November 21, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from Dec. 7-10. Data being shared at the meeting will showcase the company’s continued progress in advancing clinical research for Merck’s expanding and diverse pipeline of in",
    "url": "https://finnhub.io/api/news?id=211af28bd029cb214d6b2d2e60dd43d7f9d0e8aad1118433264a8656f90d1f1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732189500,
      "headline": "Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities",
      "id": 131541332,
      "image": "https://media.zenfs.com/en/business-wire.com/711c4a1951785e51fc2dfe84bd7f597c",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 21, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from Dec. 7-10. Data being shared at the meeting will showcase the company’s continued progress in advancing clinical research for Merck’s expanding and diverse pipeline of in",
      "url": "https://finnhub.io/api/news?id=211af28bd029cb214d6b2d2e60dd43d7f9d0e8aad1118433264a8656f90d1f1d"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference",
    "summary": "Merck &amp; Co., Inc. (NYSE:MRK) Jefferies London Healthcare Conference November 21, 2024 6:30 AM ETCorporate ParticipantsJoe Romanelli - President, Human...",
    "url": "https://finnhub.io/api/news?id=e0da027288560e25631928d7433ae470c6d504a507460ca5ae7a27206d0140f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732188384,
      "headline": "Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference",
      "id": 131540723,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck &amp; Co., Inc. (NYSE:MRK) Jefferies London Healthcare Conference November 21, 2024 6:30 AM ETCorporate ParticipantsJoe Romanelli - President, Human...",
      "url": "https://finnhub.io/api/news?id=e0da027288560e25631928d7433ae470c6d504a507460ca5ae7a27206d0140f8"
    }
  },
  {
    "ts": null,
    "headline": "Merck: to present its advances in hematology at ASH",
    "summary": "Merck announces the presentation of more than 20 abstracts on both approved and investigational drugs at the annual meeting of the American Society of Hematology , to be held December 7-10 in San...",
    "url": "https://finnhub.io/api/news?id=98eb4a7fb8535ccb19e7d165697502f377482a1d0f6d4bf2b1f2c848500d99c1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732179855,
      "headline": "Merck: to present its advances in hematology at ASH",
      "id": 131538387,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces the presentation of more than 20 abstracts on both approved and investigational drugs at the annual meeting of the American Society of Hematology , to be held December 7-10 in San...",
      "url": "https://finnhub.io/api/news?id=98eb4a7fb8535ccb19e7d165697502f377482a1d0f6d4bf2b1f2c848500d99c1"
    }
  },
  {
    "ts": null,
    "headline": "Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals",
    "summary": "A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stage study, but the company won’t be the first to market.",
    "url": "https://finnhub.io/api/news?id=a64a4c3c63a523e7ea7fa818c2332bfdb0db5e0cc4f98615757b4222a66f9efd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732173177,
      "headline": "Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals",
      "id": 131541333,
      "image": "https://imgproxy.divecdn.com/Mo4LHwDBwt4bdhZ1fBMKeswWOFHgT8mWjT44xw50-WE/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9rZXl0cnVkYS5wbmc=.webp",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stage study, but the company won’t be the first to market.",
      "url": "https://finnhub.io/api/news?id=a64a4c3c63a523e7ea7fa818c2332bfdb0db5e0cc4f98615757b4222a66f9efd"
    }
  }
]